115 related articles for article (PubMed ID: 26887702)
1. Re: Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2.
Laguna MP
J Urol; 2016 Mar; 195(3):608. PubMed ID: 26887702
[No Abstract] [Full Text] [Related]
2. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
4. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
8. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
Elsada A; Adler AI
Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
[No Abstract] [Full Text] [Related]
9. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
10. Welcome clinical leadership at NICE.
Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of axitinib through a probabilistic decision model.
Petrou P
Expert Opin Pharmacother; 2015 Jun; 16(8):1233-43. PubMed ID: 25958963
[TBL] [Abstract][Full Text] [Related]
12. We have a new treatment, but you can't afford it.
Desch CE
J Natl Compr Canc Netw; 2006 Sep; 4(8):720-3. PubMed ID: 16995283
[No Abstract] [Full Text] [Related]
13. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):61-8. PubMed ID: 19804430
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
17. Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.
Kleijnen S; Fathallah M; van der Linden MW; Vancraeynest P; Dahmani B; Timoney A; De Boer A; Leufkens HG; Goettsch WG
Value Health; 2015 Jul; 18(5):663-72. PubMed ID: 26297095
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Drug Ther Bull; 2011 Nov; 49(11):129-32. PubMed ID: 22074946
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
20. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]